Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ART 5803

Next Previous
Drug Profile

ART 5803

Alternative Names: ART-5803

Latest Information Update: 01 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arialys Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anti-N-methyl-D-aspartate receptor encephalitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anti-N-methyl-D-aspartate receptor encephalitis

Most Recent Events

  • 25 Sep 2025 US FDA grants Rare Pediatric Disease Designation to ART 5803 for Anti-N-methyl-D-aspartate receptor encephalitis in USA
  • 18 Jun 2025 Pharmacodynamics data from a preclinical studies in Anti-N-methyl-D-aspartate receptor encephalitis released by Arialys Therapeutics
  • 05 Apr 2025 Adverse events data from preclinical studies in Anti-N-methyl-D-aspartate receptor enephalitis presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top